A prospective pilot study of immunological and radiological effects of intrathecal Rituximab in patients with secondary progressive MS

Eudract nr. 2012-004436-36
End of trial date 09-09-2016

Results

The study was terminated early and before the anticipated number of patients were included. This was based on the following considerations:

1) We wanted to include patients with rapidly progressive MS. As a measure of this, we used the Expanded Disability Status Scale - EDSS for monitoring of progression. Since symptomatic treatment with Fampridine was initiated at in the same patient population at this time, we were unable to find the desired progression on EDSS in a sufficient number of patients.

2) During this study, a similar study published showed no effect on intrathecal Rituximab in secondary progressive MS. Based on this we found it unethical to continue the study.

One participant was included and completed the study.

Based on this we could not make any final conclusion on the primary or secondary endpoints.